БЛОКАДА ЦИТОКИНОВОГО ШТОРМА ПРИ ТЯЖЕЛОМ ТЕЧЕНИИ ИНФЕКЦИИ, ВЫЗВАННОЙ SARS-COV-2: МЕДИКАМЕНТОЗНАЯ СУПРЕССИЯ ИЛИ ЭКСТРАКОРПОРАЛЬНАЯ ЭЛИМИНАЦИЯ?
Аннотация
Введение. Актуальность проблемы лечения тяжелой формы COVID-19 обусловлена высокой летальностью как в общей популяции пациентов (6,4%), так и у пациентов отделений интенсивной терапии (25,8%). Цитокиновый шторм – патологическое состояние, приводящее к высокой летальности. Известны 2 подхода к снижению воспалительных цитокинов в крови: блокада их выработки медикаментозными препаратами и экстракорпоральное удаление. Однако выбор того или иного подхода остается предметом дискуссий.Цель. Провести анализ литературы по современным подходам к назначению лекарственных средств и экстракорпоральной детоксикации для блокады цитокинового шторма при тяжелой инфекции COVID-19.
Материал и методы. Проанализировано 47 литературных источников.
Результаты. Получены сведения о современных методах блокады цитокинового шторма при тяжелой инфекции COVID-19, указывающих как на эффективность тоцилизумаба, так и селективной антицитокиновой гемосорбции, плазмафереза, методов почечно-заместительной терапии.
Выводы. На основе клинических наблюдений установлено, что не только медикаментозная супрессия воспалительных цитокинов может быть эффективна в лечении тяжелых COVID-19 пневмоний, эффективны также и методы экстракорпорального очищения крови.
Литература
World Health Organization. Coronavirus disease 2019 (COVID-19). Situation Report 127. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200526-covid-19-sitrep-127.pdf?sfvrsn$=$7b6655ab_8.
Auld S, Caridi-Scheible M, Blum JM, Robichaux CJ, Kraft CS, Jacob JT, Jabaley CS, Carpenter D, Kaplow R, Hernandez AC, Adelman MW, Martin SG, Coopersmith CM, Murphy DJ. ICU and ventilator mortality among critically ill adults with COVID-19. medRxiv [Preprint]. 2020 [posted 2020 April 26]. Available from: https://doi.org/10.1101/2020.04.23.20076737
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. https://doi.org/10.1016/S0140-6736(20)30183-5
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846-848. https://doi.org/10.1007/s00134-020-05991-x
Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, Zhang X, Zhang M, Wu S, Song J, Chen T, Han M, Li S, Luo X, Zhao J, Ning Q. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. J. Clin. Invest. 2020;130(5):2620-2629. https://doi.org/10.1101/2020.02.16.20023903
Gao Y, Li T, Han M, Li X, Wu D, Xu Y, Zhu Y, Liu Y, Wang X, Wang L. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J. Med. Virol. 2020;92(7):791-796. https://doi.org/10.1002/jmv.25770
Braciale T, Hahn Y. Immunity to viruses. Immunol. Rev. 2013;255(1):5-12. https://doi.org/10.1111/imr.12109
Ragab D, Eldin HS, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; What we know so far. Front. Immunol. 2020;11:1446. https://doi.org/10.3389/fimmu.2020.01446
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-513. https://doi.org/10.1016/S0140-6736(20)30211-7
Shimizu M. Clinical features of cytokine storm syndrome. In: Cron R, Behrens, E editors. Cytokine Storm Syndrome. Cham: Springer; 2019. p. 31-42. https://doi.org/10.1007/978-3-030-22094-5_3
Şahin A, Derin ME, Albayrak F, Karakaş B, Karagöz Y. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever. Adv Rheumatol. 2020;60(1):12. https://doi.org/10.1186/s42358-020-0117-1
Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, Cron RQ, Opal SM. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of the macrophage activation syndrome: re-analysis of a prior phase III trial. Crit. Care Med. 2016;44(2):275-281. https://doi.org/10.1097/CCM.0000000000001402
Varan Ö, Kucuk H, Babaoglu H, Guven SC, Ozturk MA, Haznedaroglu S, Goker B, Tufan A. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis. Mod Rheumatol. 2019;29(2):363-366. https://doi.org/10.1080/14397595.2018.145746918.1457469.
Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, Richardson P. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet. Infect. Dis. 2020;20(4):400-402. https://doi.org/10.1016/S1473-3099(20)30132-8
Ferro F, Elefante E, Baldini C, Bartoloni E, Puxeddu I, Talarico R, Mosca M, Bombardieri S. COVID-19: the new challenge for rheumatologists. Clin. Exp. Rheumatol. 2020;38(2):175-180.
Chen H, Wang F, Zhang P, Zhang Y, Chen Y, Fan X, Cao X, Liu J, Yang Y, Wang B, Lei B, Gu L, Bai J, Wei L, Zhang R, Zhuang Q, Zhang W, Zhao W, He A. Management of cytokine release syndrome related to CAR-T cell therapy. Front. Med. 2019;13:610-617. https://doi.org/10.1007/s11684-019-0714-8
Xu X, Han M, Li T, Sun W, Wang D, Zhou Y, Zheng X, Yang Y, Li X, Zhang X, Pan A, Wei H. Effective treatment of severe COVID-19 patients with Tocilizumab. Proc. Natl. Acad. Sci. USA. 2020;117(20):10970-10975. https://doi.org/10.1073/pnas.2005615117
Jones G, Ding C. Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis. Clin. Med. Insights Arthritis Musculoskelet. Dis. 2010;3:81-89. https://doi.org/10.4137/CMAMD.S4864
Antinori S, Bonazzetti C, Gubertini G, Capetti A, Pagani C, Morena V, Rimoldi S, Galimberti L, Sarzi-Puttini P, Ridolfo AL. Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia? Autoimmun. Rev. 2020;19(7). https://doi.org/10.1016/j.autrev.2020.102564
Zhang Y, Zhong Y, Pan L, Dong J. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: are we already that far? Drug Discov. Ther. 2020;14(2):100-102. https://doi.org/10.5582/ddt.2020.03006
Ronco C, Bellomo R, Lonneman G. Sepsis: theory and therapies. N. Engl. J. Med. 2003;348(16):1600-1602. https://doi.org/10.1056/NEJM200304173481616
Ma J, Xia P, Zhou Y, Liu Z, Zhou X, Wang J, Li T, Yan X, Chen L, Zhang S, Qin Y, Li X. Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19. Clin. Immunol. 2020;214:108408. https://doi.org/10.1016/j.clim.2020.108408
Ronco C, Bagshaw SM, Bellomo R, Clark WR, HusainSyed F, Kellum JA, Ricci Z, Rimmelé T, Reis T, Ostermann M. Extracorporeal blood purification and organ support in the critically ill patient during COVID-19 pandemic: expert review and recommendation. Blood Purification. 2020:1-11. https://doi.org/10.1159/000508125
FDA. Emergency Use Authorizations for Medical Devices. Available from: https://www.fda.gov/medical-devices/ emergency-situations-medical-devices/emergency-use-authorizations.
Kellum JA, Pike F, Yealy DM, Huang DT, Shapiro NI, Angus DC. Relationship between alternative resuscitation strategies, host response and injury biomarkers, and outcome in septic shock: analysis of the protocol-based care for early septic shock study. Crit. Care Med. 2017;45(3):438445. https://doi.org/10.1097/CCM.0000000000002206
Esmaeili Vardanjani A, Ronco C, Rafiei H, Golitaleb M, Pishvaei MH, Mohammadi M. Early hemoperfusion for cytokine removal may contribute to prevention of intubation in patients infected with COVID-19. Blood Purif. 2020;1-4. https://doi.org/10.1159/000509107
Stockmann H, Keller T, Büttner S, Jörres A, Kindgen-Milles D, Kunz JV, Leebmann J, Spies C, Träger K, Treskatsch S, Uhrig A, Willam C, Enghard P, Slowinski T. CytoResc - "CytoSorb" rescue for critically ill patients undergoing the COVID-19 cytokine storm: a structured summary of a study protocol for a randomized controlled trial. Trials. 2020;21(1):577. https://doi.org/10.1186/s13063-020-04501-0
Napp LC, Bauersachs J. Extracorporeal hemoadsorption an option for COVID-19 associated cytokine storm syndrome. Shock. 2020. https://doi.org/10.1097/SHK.0000000000001568
Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, Maffei C, Possenti S, Gaggia P, Movilli E, Bove S, Malberti F, Farina M, Bracchi M. Management of patients on dialysis and with kidney transplant during COVID-19 coronavirus infection. G. Ital. Nefrol. 2020;37(2);1-6. https://doi.org/10.22141/2307-1257.9.2.2020.203411
Keith P, Day M, Perkins L, Moyer L, Hewitt K, Wells A. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19. Crit. Care. 2020;24(1):128. https://doi.org/10.1186/s13054-020-2836-4
Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):14171418. https://doi.org/10.1016/S0140-6736(20)30937-5
Keith P, Day M, Perkins L, Moyer L, Hewitt K, Wells A. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19. Crit. Care. 2020;24(1):128. https://doi.org/10.1186/s13054-020-2836-4
Stahl K, Bode C, David S. First do no harm-beware the risk of therapeutic plasma exchange in severe COVID-19. Crit. Care. 2020;24(1):363. https://doi.org/10.1186/s13054-020-03070-7
Honore PM, Mugisha A, Kugener L, Redant S, Attou R, Gallerani A, De Bels D. Therapeutic plasma exchange as a routine therapy in septic shock and as an experimental treatment for COVID-19: we are not sure. Crit. Care. 2020;24(1):226. https://doi.org/10.1186/s13054-020-02943-1
Padmanabhan A, Connelly-Smith L, Aqui N. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American Society for Apheresis: the eight special issue. J. Clin. Apher. 2019;34(3):171-354. https://doi.org/10.1002/jca.21705
Keith P, Day M, Choe C, Perkins L, Moyer L, Hays E, French M, Hewitt K, Gravel G, Guffey A, Scott LK. The successful use of therapeutic plasma exchange for severe COVID-19 acute respiratory distress syndrome with multiple organ failure. SAGE Open Med. Case Rep. 2020;8:2050313X20933473. https://doi.org/10.1177/2050313X20933473
Dogan L, Kaya D, Sarikaya T, Zengin R, Dincer A, Akinci IO, Afsar N. Plasmapheresis treatment in COVID-19related autoimmune meningoencephalitis: Case series. Brain Behav. Immun. 2020;87:155-158. https://doi.org/10.1016/j.bbi.2020.05.022
Lin JH, Chen YC, Lu CL, Hsu YN, Wang WJ. Application of plasma exchange in association with higher dose CVVH in cytokine storm complicating COVID-19. Med. Assoc. 2020;119(6):1116-1118. https://doi.org/10.1016/j.jfma.2020.04.023
Luo S, Yang L, Wang C, Liu C, Li D. Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020;49(2):227-231. https://doi.org/10.3785/J.ISSN.10089292.2020.03.06
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, [et al]. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020;382(18):1708-1720. https://doi.org/10.1101/2020.02.06.20020974
Adapa S, Aeddula NR, Konala VM, Chenna A, Naramala S, Madhira BR, Gayam V, Balla M, Muppidi V, Bose S. COVID-19 and renal failure: challenges in the delivery of renal replacement therapy. J. Clin. Med. Res. 2020;12(5):276-285. https://doi.org/10.14740/jocmr4160
Panitchote A, Mehkri O, Hastings A, Hanane T, Demirjian S, Torbic H, Mireles-Cabodevila E, Krishnan S, Duggal A. Factors associated with acute kidney injury in acute respiratory distress syndrome. Ann. Intensive Care. 2019;9:110. https://doi.org/10.1186/s13613-019-0552-5
Dastan F, Saffaei A, Mortazavi SM, Jamaati H, Adnani N, Roudi SS, Kiani A, Abedini A, Hashemian SMR. Continues renal replacement therapy (CRRT) with disposable hemoperfusion cartridge: a promising option for severe COVID-19. J. Glob. Antimicrob. Resist. 2020;21:340341. https://doi.org/10.1016/j.jgar.2020.04.024
Nalesso F, Garzotto F, Cattarin L, Gobbi L, Qassim L, Sgarabotto L, Tiberio I, Calò LA. A continuous renal replacement therapy protocol for patients with acute kidney injury in intensive care unit with COVID-19. J. Clin. Med. 2020;9(5):1529. https://doi.org/10.3390/jcm9051529
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. https://doi.org/10.1016/S0140-6736(20)30566-3
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270273. https://doi.org/10.1038/s41586-020-2012-7
Yang Y, Shi J, Ge S, Guo S, Xing X, Wang Y, Cheng A, Liu Q, Li J, Ning Y, He F, Xu G. Effect of continuous renal replacement therapy on all-cause mortality in COVID-19 patients undergoing invasive mechanical ventilation: a retrospective cohort study. medRxiv [Preprint]. 2020. [posted 2020 March 20]. Available from: https://doi.org/10.1101/2020.03.16.20036780
